 Quality-Adjusted Life Years
"Quality-Adjusted Life Years" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A measurement index derived from a modification of standard life-table procedures and designed to take account of the quality as well as the duration of survival. This index can be used in assessing the outcome of health care procedures or services. (BIOETHICS Thesaurus, 1994)
| Descriptor ID |
D019057
|
| MeSH Number(s) |
E05.318.740.100.500.700 L01.280.975.475.700 N01.224.935.530.700
|
| Concept/Terms |
Quality-Adjusted Life Years- Quality-Adjusted Life Years
- Life Year, Quality-Adjusted
- Life Years, Quality-Adjusted
- Quality-Adjusted Life Year
- Year, Quality-Adjusted Life
- Years, Quality-Adjusted Life
- QALY
- Quality Adjusted Life Years
Adjusted Life Years- Adjusted Life Years
- Adjusted Life Year
- Life Year, Adjusted
- Life Years, Adjusted
- Year, Adjusted Life
- Years, Adjusted Life
|
Below are MeSH descriptors whose meaning is more general than "Quality-Adjusted Life Years".
Below are MeSH descriptors whose meaning is more specific than "Quality-Adjusted Life Years".
This graph shows the total number of publications written about "Quality-Adjusted Life Years" by people in this website by year, and whether "Quality-Adjusted Life Years" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 3 | 3 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 0 | 2 | | 2000 | 1 | 0 | 1 | | 2001 | 0 | 2 | 2 | | 2002 | 2 | 0 | 2 | | 2003 | 0 | 5 | 5 | | 2005 | 0 | 2 | 2 | | 2006 | 0 | 2 | 2 | | 2007 | 1 | 3 | 4 | | 2008 | 1 | 1 | 2 | | 2009 | 0 | 2 | 2 | | 2010 | 0 | 2 | 2 | | 2011 | 1 | 2 | 3 | | 2012 | 2 | 3 | 5 | | 2013 | 0 | 4 | 4 | | 2014 | 1 | 5 | 6 | | 2015 | 2 | 3 | 5 | | 2016 | 0 | 7 | 7 | | 2017 | 1 | 3 | 4 | | 2018 | 0 | 7 | 7 | | 2019 | 0 | 7 | 7 | | 2020 | 1 | 8 | 9 | | 2021 | 0 | 6 | 6 | | 2022 | 0 | 3 | 3 |
To return to the timeline, click here.
Below are the most recent publications written about "Quality-Adjusted Life Years" by people in Profiles.
-
Choi JG, Winn AN, Skandari MR, Franco MI, Staab EM, Alexander J, Wan W, Zhu M, Huang ES, Philipson L, Laiteerapong N. First-Line Therapy for Type 2 Diabetes With Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists : A Cost-Effectiveness Study. Ann Intern Med. 2022 10; 175(10):1392-1400.
-
Podolsky MI, Present I, Neumann PJ, Kim DD. A Systematic Review of Economic Evaluations of COVID-19 Interventions: Considerations of Non-Health Impacts and Distributional Issues. Value Health. 2022 08; 25(8):1298-1306.
-
Ma S, Olchanski N, Cohen JT, Ollendorf DA, Neumann PJ, Kim DD. The Impact of Broader Value Elements on Cost-Effectiveness Analysis: Two Case Studies. Value Health. 2022 08; 25(8):1336-1343.
-
Silver MC, Neumann PJ, Ma S, Kim DD, Cohen JT, Nyaku M, Roberts C, Sinha A, Ollendorf DA. Frequency and impact of the inclusion of broader measures of value in economic evaluations of vaccines. Vaccine. 2021 11 05; 39(46):6727-6734.
-
van Dover TJ, Kim DD. Do Centers for Medicare and Medicaid Services Quality Measures Reflect Cost-Effectiveness Evidence? Value Health. 2021 11; 24(11):1586-1591.
-
Mojtahed SA, Boyer NR, Rao SA, Gajewski TF, Tseng J, Turaga KK. Cost-Effectiveness Analysis of Adjuvant Therapy for BRAF-Mutant Resected Stage III Melanoma in Medicare Patients. Ann Surg Oncol. 2021 Dec; 28(13):9039-9047.
-
Ackroyd SA, Huang ES, Kurnit KC, Lee NK. Pembrolizumab and lenvatinib versus carboplatin and paclitaxel as first-line therapy for advanced or recurrent endometrial cancer: A Markov analysis. Gynecol Oncol. 2021 08; 162(2):249-255.
-
Kim DD, Do LA, Daly AT, Wong JB, Chambers JD, Ollendorf DA, Neumann PJ. An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. J Gen Intern Med. 2021 11; 36(11):3448-3455.
-
Shaffer SR, Huang E, Patel S, Rubin DT. Cost-Effectiveness of 5-Aminosalicylate Therapy in Combination With Biologics or Tofacitinib in the Treatment of Ulcerative Colitis. Am J Gastroenterol. 2021 01 01; 116(1):125-133.
-
Kim DD, Silver MC, Kunst N, Cohen JT, Ollendorf DA, Neumann PJ. Perspective and Costing in Cost-Effectiveness Analysis, 1974-2018. Pharmacoeconomics. 2020 10; 38(10):1135-1145.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|